inovmedИнновационная медицина КубаниInnovative Medicine of Kuban2541-9897Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1inovmed-1496Research ArticleСтатьиЛучевая диагностика токсического поражения спинного мозга и периферической нервной системы как иммуноопосредованного осложнения противоопухолевой терапииRadiologic Diagnosis of Toxic Injury to Spinal Cord and Peripheral Nervous System as an Immune-Mediated Complication of Antitumor Therapyhttps://orcid.org/0009-0009-4355-6301ГерасютаА. Е.GerasyutaA. E.

Герасюта Анна Евгеньевна, врач-рентгенолог рентгеновского отделения; ассистент кафедры лучевой диагностики № 2

350086, Краснодар, ул. 1 Мая, 167

Anna E. Gerasyuta, Radiologist, Radiology Department; Assistant Professor, Radiology Department No. 2

167 1 Maya St., Krasnodar, 350086

annagerasuta@mail.ruhttps://orcid.org/0009-0002-4743-7907КривицкаяЕ. Ю.KrivitskayaE. Yu.

Кривицкая Елена Юрьевна, врач-рентгенолог рентгеновского отделения; ассистент кафедры лучевой диагностики № 2

Краснодар

Elena Yu. Krivitskaya, Radiologist, Radiology Department; Assistant Professor, Radiology Department No. 2

Krasnodar

https://orcid.org/0009-0000-2245-9400ХахилеваА. Е.KhakhilevaA. E.

Хахилева Анастасия Евгеньевна, врач-рентгенолог рентгеновского отделения

Краснодар

Anastasia E. Khakhileva, Radiologist, Radiology Department

Krasnodar

https://orcid.org/0000-0003-0572-1395ПорхановВ. А.PorhanovV. A.

Порханов Владимир Алексеевич, академик РАН, профессор, д.м.н., главный врач; заведующий кафедрой онкологии с курсом торакальной хирургии

Краснодар

Vladimir A. Porhanov, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Chief Physician; Head of the Oncology Department with the Thoracic Surgery Course, Faculty of Continuing Professional Development and Retraining

Krasnodar

ГБУЗ «НИИ – ККБ № 1 им. проф. С.В. Очаповского» Минздрава Краснодарского края; ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава РоссииРоссияScientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical UniversityRussian FederationГБУЗ «НИИ – ККБ № 1 им. проф. С.В. Очаповского» Минздрава Краснодарского краяРоссияScientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1Russian Federation202630032026111-1Приложение311Copyright © Герасюта А.Е., Кривицкая Е.Ю., Хахилева А.Е., Порханов В.А., 20262026Герасюта А.Е., Кривицкая Е.Ю., Хахилева А.Е., Порханов В.А.Gerasyuta A.E., Krivitskaya E.Y., Khakhileva A.E., Porhanov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.innovmedkub.ru/jour/article/view/1496

Иммунотерапия представляет собой значительный прорыв в современной онкологии и успешно применяется для лечения различных злокачественных новообразований, особенно тех, что находятся на поздних стадиях метастазирования. Этот подход продемонстрировал впечатляющие терапевтические результаты в борьбе с онкологическими заболеваниями, однако в некоторых случаях иммунотерапия может приводить к развитию атипичных реакций, называемых иммуноопосредованными нежелательными явлениями (immune-related adverse events, irAE). Токсическое поражение спинного мозга и периферической нервной системы, возникающее в результате осложнений противоопухолевой терапии, представляет собой серьёзную клиническую проблему. Особенно актуальны такие проявления, как демиелинизирующие процессы, миелиты, синдром Гийена-Барре, поражение черепных нервов, плексопатии и миозиты. Оперативное выявление этих осложнений с помощью методов лучевой диагностики имеет решающее значение для улучшения прогноза и исхода заболевания у пациентов, получающих иммунотерапию. 

Immunotherapy represents a significant breakthrough in modern oncology, being successfully used in the treatment of various malignant neoplasms including those at advanced metastatic stages. This approach has demonstrates impressive therapeutic outcomes in the management of cancer; however, in certain cases, it may lead to the development of atypical reactions known as immune-related adverse events (irAEs). Toxic injury to the spinal cord and peripheral nervous system resulting from complications of antitumor therapy constitutes a serious clinical challenge. Among particularly relevant manifestations are demyelinating disorders, myelitis, Guillain-Barré syndrome, cranial neuropathies, plexopathies, and myositis. Timely detection of these complications using imaging modalities is essential for improving prognosis and clinical outcomes in patients receiving immunotherapy.

онкологияингибиторы контрольных точекиммунотерапияиммуноопосредованные нежелательные явленияосложненияМРТКТoncologycheckpoint inhibitorsimmunotherapyimmune-related adverse eventscomplicationsMRICTReferencesЗяблова Е.И., Нефедова Л.Н., Порханов В.А. Лучевая диагностика иммунотерапевтических осложнений. Онкологический журнал: лучевая диагностика, лучевая терапия. 2020;3(3):44-53. DOI: 10.37174/2587-7593-2020-3-3-44-53Зяблова Е.И., Нефедова Л.Н., Порханов В.А. Лучевая диагностика иммунотерапевтических осложнений. Онкологический журнал: лучевая диагностика, лучевая терапия. 2020;3(3):44-53. DOI: 10.37174/2587-7593-2020-3-3-44-53Nagai H, Muto M. Optimal management of immunerelated adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Int J Clin Oncol. 2018 Jun;23(3):410-420. doi: 10.1007/s10147-018-1259-6. Epub 2018 Mar 7. PMID: 29516216.Nagai H, Muto M. Optimal management of immunerelated adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Int J Clin Oncol. 2018 Jun;23(3):410-420. doi: 10.1007/s10147-018-1259-6. Epub 2018 Mar 7. PMID: 29516216.El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017 Nov;119:1-12. doi: 10.1016/j.critrevonc.2017.09.002. Epub 2017 Sep 8. PMID: 29065979.El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017 Nov;119:1-12. doi: 10.1016/j.critrevonc.2017.09.002. Epub 2017 Sep 8. PMID: 29065979.Зяблова Е. И. Визуализация побочных эффектов противоопухолевой терапии / Е. И. Зяблова. – Краснодар: Кубанский государственный медицинский университет, 2025. – 156 с. – EDN YCEOIW.Зяблова Е. И. Визуализация побочных эффектов противоопухолевой терапии / Е. И. Зяблова. – Краснодар: Кубанский государственный медицинский университет, 2025. – 156 с. – EDN YCEOIW.Pozzessere C, Mazini B, Omoumi P, Jreige M, Noirez L, Digklia A, Fasquelle F, Sempoux C, Dromain C. Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy: A Comprehensive Imaging-Based Review. Cancers (Basel). 2024 Jul 19;16(14):2585. doi: 10.3390/cancers16142585. PMID: 39061225; PMCID: PMC11274393.Pozzessere C, Mazini B, Omoumi P, Jreige M, Noirez L, Digklia A, Fasquelle F, Sempoux C, Dromain C. Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy: A Comprehensive Imaging-Based Review. Cancers (Basel). 2024 Jul 19;16(14):2585. doi: 10.3390/cancers16142585. PMID: 39061225; PMCID: PMC11274393.Picca A, Berzero G, Bihan K, Jachiet V, Januel E, Coustans M, Cauquil C, Perrin J, Berlanga P, Kramkimel N, Garel B, Devic P, Ducray F, Benazra M, Bompaire F, Leclercq D, Michot JM, Ammari S, Psimaras D. Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors. Neurol Neuroimmunol Neuroinflamm. 2021 Feb 26;8(3):e967. doi: 10.1212/NXI.0000000000000967. PMID: 33637598; PMCID: PMC7954463.Picca A, Berzero G, Bihan K, Jachiet V, Januel E, Coustans M, Cauquil C, Perrin J, Berlanga P, Kramkimel N, Garel B, Devic P, Ducray F, Benazra M, Bompaire F, Leclercq D, Michot JM, Ammari S, Psimaras D. Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors. Neurol Neuroimmunol Neuroinflamm. 2021 Feb 26;8(3):e967. doi: 10.1212/NXI.0000000000000967. PMID: 33637598; PMCID: PMC7954463.Oliveira MCB, de Brito MH, Simabukuro MM. Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature. Front Neurol. 2020 Dec 11;11:538695. doi: 10.3389/fneur.2020.538695. PMID: 33362680; PMCID: PMC7759512.Oliveira MCB, de Brito MH, Simabukuro MM. Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature. Front Neurol. 2020 Dec 11;11:538695. doi: 10.3389/fneur.2020.538695. PMID: 33362680; PMCID: PMC7759512.Han C, Ma JA, Zhang Y, Jiang Y, Hu C, Wu Y. GuillainBarre syndrome induced by pembrolizumab and sunitinib: A case report. Mol Clin Oncol. 2020 Jul;13(1):38-42. doi: 10.3892/mco.2020.2042. Epub 2020 May 5. PMID: 32499912; PMCID: PMC7265222.Han C, Ma JA, Zhang Y, Jiang Y, Hu C, Wu Y. GuillainBarre syndrome induced by pembrolizumab and sunitinib: A case report. Mol Clin Oncol. 2020 Jul;13(1):38-42. doi: 10.3892/mco.2020.2042. Epub 2020 May 5. PMID: 32499912; PMCID: PMC7265222.Li Y, Zhang X, Zhao C. Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases. Biomed Res Int. 2021 Aug 19;2021:9800488. doi: 10.1155/2021/9800488. PMID: 34458371; PMCID: PMC8390151.Li Y, Zhang X, Zhao C. Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases. Biomed Res Int. 2021 Aug 19;2021:9800488. doi: 10.1155/2021/9800488. PMID: 34458371; PMCID: PMC8390151.Cherukuri PB, Tayyeb M, Gaddameedi SR, Du D, Meghal T. Pembrolizumab-induced Guillain-Barré syndrome in triple-negative breast cancer: A case report. World J Clin Oncol 2025; 16(2): 9782Cherukuri PB, Tayyeb M, Gaddameedi SR, Du D, Meghal T. Pembrolizumab-induced Guillain-Barré syndrome in triple-negative breast cancer: A case report. World J Clin Oncol 2025; 16(2): 9782Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25;372(26):2521- 32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19. PMID: 25891173.Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25;372(26):2521- 32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19. PMID: 25891173.Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018Feb 14. PMID: 29442540; PMCID: PMC6481621.Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018Feb 14. PMID: 29442540; PMCID: PMC6481621.Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27. doi: 10.1016/S0140-6736(16)00339-1. Epub 2016 Mar 2. PMID: 26948435.Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27. doi: 10.1016/S0140-6736(16)00339-1. Epub 2016 Mar 2. PMID: 26948435.Никитин С. С., Борискина Л. М. Иммуноглобулины в неврологической практике: обзор литературы. Нервно-мышечные болезни 2019;9(1):32–51.Никитин С. С., Борискина Л. М. Иммуноглобулины в неврологической практике: обзор литературы. Нервно-мышечные болезни 2019;9(1):32–51.Vieira GD, Boldrini VO, Schlindwen L, de Souza Filho ECP, Schulz ME, de Souza FF, Trevisani JP, Campezato PH, Haag A, Gonçalves MVM. Cranial neuropathies related to immune checkpoint inhibitors. J Neuroimmunol. 2025 Dec 15;409:578752. doi: 10.1016/j.jneuroim.2025.578752. Epub 2025 Sep 8. PMID: 40957152.Vieira GD, Boldrini VO, Schlindwen L, de Souza Filho ECP, Schulz ME, de Souza FF, Trevisani JP, Campezato PH, Haag A, Gonçalves MVM. Cranial neuropathies related to immune checkpoint inhibitors. J Neuroimmunol. 2025 Dec 15;409:578752. doi: 10.1016/j.jneuroim.2025.578752. Epub 2025 Sep 8. PMID: 40957152.Dang, Y., Wang, M., Li, W. et. al. Facial nerve injury immune related adverse events associated with adjuvant pembrolizumab therapy: A case report. World Academy of Sciences Journal, 2, 22. https://doi.org/10.3892/wasj.2020.63.Dang, Y., Wang, M., Li, W. et. al. Facial nerve injury immune related adverse events associated with adjuvant pembrolizumab therapy: A case report. World Academy of Sciences Journal, 2, 22. https://doi.org/10.3892/wasj.2020.63.Wilson M.A., Guld K., Galetta S. et. al. Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer. 2016 Oct 18;4:66. doi: 10.1186/s40425-016-0170-9. PMID: 27777775; PMCID: PMC5067900Wilson M.A., Guld K., Galetta S. et. al. Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer. 2016 Oct 18;4:66. doi: 10.1186/s40425-016-0170-9. PMID: 27777775; PMCID: PMC5067900Alhammad RM, Dronca RS, Kottschade LA, Turner HJ, Staff NP, Mauermann ML, Tracy JA, Klein CJ. Brachial Plexus Neuritis Associated With Anti-Programmed Cell Death-1 Antibodies: Report of 2 Cases. Mayo Clin Proc Innov Qual Outcomes. 2017 Sep 1;1(2):192-197. doi: 10.1016/j.mayocpiqo.2017.07.004. PMID: 30225416; PMCID: PMC6134904.Alhammad RM, Dronca RS, Kottschade LA, Turner HJ, Staff NP, Mauermann ML, Tracy JA, Klein CJ. Brachial Plexus Neuritis Associated With Anti-Programmed Cell Death-1 Antibodies: Report of 2 Cases. Mayo Clin Proc Innov Qual Outcomes. 2017 Sep 1;1(2):192-197. doi: 10.1016/j.mayocpiqo.2017.07.004. PMID: 30225416; PMCID: PMC6134904.Park C, Kim KT. Demyelinating polyneuropathy combined with brachial plexopathy after nivolumab therapy for hodgkin lymphoma: a case report. BMC Neurol. 2023 Mar 30;23(1):130. doi: 10.1186/s12883-023-03177-8. PMID: 36997886; PMCID: PMC10061856.Park C, Kim KT. Demyelinating polyneuropathy combined with brachial plexopathy after nivolumab therapy for hodgkin lymphoma: a case report. BMC Neurol. 2023 Mar 30;23(1):130. doi: 10.1186/s12883-023-03177-8. PMID: 36997886; PMCID: PMC10061856.Vicino A, Hottinger AF, Latifyan S, Boughdad S, Becce F, Prior JO, Kuntzer T, Brouland JP, Dunet V, Obeid M, Théaudin M. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series. J Neurol. 2024 Apr;271(4):1947-1958. doi: 10.1007/s00415-023-12134-x. Epub 2023 Dec 23. PMID: 38141128; PMCID: PMC10973051.Vicino A, Hottinger AF, Latifyan S, Boughdad S, Becce F, Prior JO, Kuntzer T, Brouland JP, Dunet V, Obeid M, Théaudin M. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series. J Neurol. 2024 Apr;271(4):1947-1958. doi: 10.1007/s00415-023-12134-x. Epub 2023 Dec 23. PMID: 38141128; PMCID: PMC10973051.Marini A, Bernardini A, Gigli GL, Valente M, Muñiz-Castrillo S, Honnorat J, Vogrig A. Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology. 2021 Apr 20;96(16):754-766. doi: 10.1212/WNL.0000000000011795. Epub 2021 Mar 2. PMID: 33653902.Marini A, Bernardini A, Gigli GL, Valente M, Muñiz-Castrillo S, Honnorat J, Vogrig A. Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology. 2021 Apr 20;96(16):754-766. doi: 10.1212/WNL.0000000000011795. Epub 2021 Mar 2. PMID: 33653902.

The authors declare that there are no conflicts of interest present.